Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin.
Larsen JT, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Wu W, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ, Litzow MR. Larsen JT, et al. Among authors: litzow mr. Leuk Lymphoma. 2013 Aug;54(8):1713-8. doi: 10.3109/10428194.2012.753444. Epub 2012 Dec 31. Leuk Lymphoma. 2013. PMID: 23189958 Clinical Trial.
Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission.
Litzow MR, Pérez WS, Klein JP, Bolwell BJ, Camitta B, Copelan EA, Gale RP, Giralt SA, Keating A, Lazarus HM, Marks DI, McCarthy PL, Miller CB, Milone G, Prentice HG, Russell JA, Schultz KR, Trigg ME, Weisdorf DJ, Horowitz MM. Litzow MR, et al. Br J Haematol. 2002 Dec;119(4):1115-24. doi: 10.1046/j.1365-2141.2002.03973.x. Br J Haematol. 2002. PMID: 12472596 Free article.
Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator.
Litzow MR, Repoussis PD, Schroeder G, Schembri-Wismayer D, Batts KP, Anderson PM, Arndt CA, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Noël P, Solberg LA Jr, Letendre L, Hoagland HC. Litzow MR, et al. Leuk Lymphoma. 2002 Nov;43(11):2099-107. doi: 10.1080/1042819021000032962. Leuk Lymphoma. 2002. PMID: 12533034
491 results